SMS Pharma completes remote regulatory assessment by USFDA; Stock climbs 4%

22 Mar 2022 , 11:44 AM

SMS Pharmaceuticals Ltd has announced the successful completion of remote regulatory assessment by USFDA for its testing facility, SMS Pharmaceuticals Limited (Central Laboratory Analytical Services) situated at Gagillapur Village, Medchal-Malkajgiri District, Hyderabad, Telangana and received Remote Assessment Report.

As a result of this remote assessment, USFDA does not plan to take or recommend regulatory or enforcement action at this time.

In a regulatory filing, the company said, “It is committed to meeting the highest quality standards and is further committed to full compliance with cGMP & GLP regulations at all our manufacturing & Analytical facilities. The “Central Laboratory Analytical Services” is an independent testing laboratory, and this was the first Remote Regulatory Assessment by USFDA and completed successfully.”

At around 11:45 AM, SMS Pharmaceuticals was trading at Rs112 apiece up by Rs4.3 or 3.99% on Sensex.